MiNK Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
MiNK Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.000.000.00
Cost of Revenue0.220.000.000.000.00
Gross Profit-0.220.000.000.000.00
Operating Expenses
Research & Development6.3415.4923.1213.979.51
Selling, General & Administrative4.317.437.834.641.29
Operating Expenses10.6522.9230.9518.6110.80
Operating Income-10.65-22.92-30.95-18.61-10.80
Other Income/Expense
Interest Income0.170.460.250.000.00
Interest Expense0.000.000.00-2.43-2.44
Other Income/Expense-0.310.00-0.090.630.35
Income
Income Before Tax-10.78-22.46-27.99-30.21-16.24
Income Tax Expense0.00-1.69-0.10-0.510.00
Net Income-10.78-22.46-27.99-30.21-16.24
Net Income - Continuous Operations-10.78-22.46-27.99-30.210.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-10.43-24.41-30.83-18.53-10.74
EBIT-10.65-24.61-30.95-18.61-10.80
Depreciation & Amortization0.220.200.120.080.06
Earnings Per Share
Basic EPS-3.00-6.00-8.00-12.00-7.00
Diluted EPS-3.00-6.00-8.00-12.00-7.00
Basic Shares Outstanding3.773.443.372.602.41
Diluted Shares Outstanding3.773.443.372.602.41